For Immediate Release: April 28, 2021 Statement From: Statement Author Leadership Role Acting Commissioner of Food and Drugs - Food and Drug Administration Janet Woodcock M.D. Being transparent about the results of completed clinical trials enables important a

Fund III will be invested in early-stage therapeutics and healthcare technology companies Qiming Venture Partners USA (Qiming US), a leading US healthcare investment firm, today announced the closing of its third fund, raising $260 million in an oversubscribed fundraise with strong support from new and existing investors. Qiming US will continue to execute on the same strategy as previous funds, deploying Fund III in early-stage therapeutics and healthcare technology companies in the US and EU that aim to improve patient outcomes and address unmet medical needs. "We are incredibly proud of the entrepreneurs and healthcare innovations we have supported in just a few short years, and we are

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the successful completion of the acquisition of Acceleron Pharma Inc. (NASDAQ:XLRN). "This is an important and strategic opportunity for our company to continue growing our cardiovascular portfolio and pipeline, that builds on our long and proud legacy in cardiovascular disease and further bolsters our business development strategy," said Rob Davis, chief executive officer and president, Merck. "Fueled by Acceleron's groundbreaking research, we are excited to explore the opportunities and possibilities ahead to reach even more patients by addressing this critical health need." Acceleron is focused on harn

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, Astros Merger Sub, Inc., for all of the outstanding shares of common stock of Acceleron Pharma Inc. (NASDAQ:XLRN), at a purchase price of $180 per share in cash, without interest and less applicable tax withholding. As of the tender offer expiration at 5:00 p.m., Eastern Time, on Nov. 19, 2021, 38,752,614 shares of common stock of Acceleron were validly tendered and not withdrawn from the tender offer, representing approximately 63.3% of the total number of Acceleron's outstanding shares. All such shares have been accepted for payment

Believes Transaction Comes at the Wrong Time, With the Wrong Price, and Following the Wrong Process Remains Confident in Company's Standalone Opportunities – Given Strong Momentum and Near-Term Inflection Point Coming from Phase 3 Data Stands Ready to Help an Independent Acceleron Succeed Avoro Capital Advisors ("Avoro"), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed funds ("Avoro," "we" or "us") beneficially owns approximately 7% of Acceleron Pharma Inc. (NASDAQ:XLRN) ("Acceleron," "XLRN" or the "Company"), making Avoro one of the Company's most significant shareholders. Avoro today issued the fol

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with Merck's pending acquisition of Acceleron Pharma Inc. (NASDAQ:XLRN) expired at 11:59 p.m., Eastern Time, on Nov. 16, 2021. As previously announced on Oct. 12, 2021, Merck commenced, through a subsidiary, Astros Merger Sub, Inc., a cash tender offer to purchase all outstanding shares of common stock of Acceleron, for $180 in cash, without interest and less any required tax withholding. The expiration of the HSR waiting period satisfies one of the conditions necessary for the consumma

Believes Now Is the Wrong Time to Cash out of Acceleron, Given Company's Strong Momentum and Near-Term Inflection Point Coming from Phase 3 Data Sees Continuing as Standalone Entity as Clearly Superior Path for Acceleron Highlights What It Believes Was a Flawed and Inadequate Sale Process, Including Not Pursuing Other Strategic Alternatives Avoro Stands Ready to Support an Independent Acceleron Avoro Capital Advisors ("Avoro"), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed funds ("Avoro," "we" or "us") beneficially owns approximately 7% of Acceleron Pharma Inc. (NASDAQ:XLRN) ("Acceleron", "XLRN" o

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that its pending acquisition of Acceleron Pharma Inc. (NASDAQ:XLRN) has been cleared by the competition authorities in Germany and Austria. As previously announced on October 12, 2021, Merck commenced, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Acceleron, for $180 in cash, without interest and less any required tax withholding. The receipt of antitrust clearance from the competition authorities in Germany and Austria satisfies one of the conditions necessary for the consummation of the tender offer. Consummation of the tender offer remains subject to oth

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it has withdrawn its Premerger Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), in connection with Merck's pending acquisition of Acceleron Pharma Inc. (NASDAQ:XLRN). As previously announced on October 12, 2021, Merck commenced, through a subsidiary, Astros Merger Sub, Inc., a cash tender offer to purchase all outstanding shares of common stock of Acceleron, for $180 in cash, without interest and less any required tax withholding. Merck has elected to withdraw its Premerger Notification and Report Form, which was initially filed o

Remains Opposed to Sale of Acceleron to Merck at Current Price and Plans Not to Tender Its Shares Believes Company Has Strong Momentum and Continuing as Standalone Entity is Superior Path to a Transaction at the Proposed Price, Particularly with Major Value Inflection Point Coming from Phase 3 Data Outlines Alternatives by Which Acceleron Could Maximize Shareholder Value as Independent Company, Including by Monetizing Royalties Ready and Willing to Assist with Change in Board Composition to Better Position Company for Go-Forward Strategy Avoro Capital Advisors ("Avoro"), a long-term and collaborative investor in life sciences and biotechnology companies, beneficially owns approximately

Believes proposed $180/share offer price is too low and that Acceleron's share price as a standalone company will exceed offer price by at least 2-2.5x Darwin Global Management Limited ("Darwin Global"), a long-term investor in the biotechnology and pharmaceutical sector and beneficial owner of 2,345,620 shares of common stock of Acceleron Pharma Inc. (NASDAQ:XLRN) ("Acceleron" or the "Company"), representing approximately 3.84% of the total outstanding shares of the Company's common stock, today issued the following letter to Acceleron shareholders. In the letter, Darwin Global urges shareholders not to tender their shares to Merck (NYSE:MRK) ("Merck") in connection with its planned acqui

Remains Opposed to Sale of Acceleron to Merck at Current Price and Plans Not to Tender Its Shares Believes Company Has Strong Momentum and Continuing as Standalone Entity is Superior Path to a Transaction at the Proposed Price, Particularly with Major Value Inflection Point Coming from Phase 3 Data Outlines Alternatives by Which Acceleron Could Maximize Shareholder Value as Independent Company, Including by Monetizing Royalties Ready and Willing to Assist with Change in Board Composition to Better Position Company for Go-Forward Strategy Avoro Capital Advisors ("Avoro"), a long-term and collaborative investor in life sciences and biotechnology companies, beneficially owns approximately

Reports Second Quarter Revenues of $11.7 Billion, an Increase of 16% YoY, or 13% When Adjusted for Foreign Exchange Posts Second Quarter Earnings Per Share of $0.47 and Non-GAAP EPS of $1.93 Delivers Strong Commercial Performance, Including Opdivo's Return to Growth and Momentum across New Product Portfolio Achieves Significant Regulatory and Clinical Milestones across Product Pipeline Further Strengthens Pipeline through Disciplined Business Development Agreements, including with Agenus and Eisai Adjusts GAAP and Reaffirms Non-GAAP EPS Guidance for 2021 Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2021, which reflect robust product sales, co

SC 13D/A - ACCELERON PHARMA INC (0001280600) (Subject)

SC 13G/A - ACCELERON PHARMA INC (0001280600) (Subject)

SC 13D - ACCELERON PHARMA INC (0001280600) (Subject)

SC 13G/A - ACCELERON PHARMA INC (0001280600) (Subject)

SC 13G/A - ACCELERON PHARMA INC (0001280600) (Subject)

SC 13G/A - ACCELERON PHARMA INC (0001280600) (Subject)